1. Scrip
  2. >>Therapy Areas

Autolus Raises $80m To Take T-Cell Engineering To The Next Level

 
• By Sten Stovall

Three-year-old clinical-stage UK biotech Autolus will use its $80m (£59m) Series C financing to advance three dual targeting CAR-T candidates in the clinic and build capacity.

Dollars
Autolus Gets $80m Series C Funding • Source: Shutterstock

Flush with fresh funds, Autolus Ltd. will now advance its next-generation engineered T-cell therapies in the clinic to generate data which it hopes will support accelerated regulatory approvals further down the line, according to its CEO Christian Itin.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immuno-oncology

More from Anticancer